THE ACCESS & EVIDENCE record
BPC-157 TB-500 is the two-peptide Wolverine research blend, read constituent by constituent.
BPC-157 supplies a local cytoprotective and pro-angiogenic signal; TB-500 supplies an actin-sequestering cell-migration signal. Both are preclinical, both unapproved, and no controlled trial has tested the two together. Here is what the literature shows and where it stops.
Two peptides, two mechanisms, one repair goal
BPC-157 TB-500 is the research-community name for a two-peptide pairing marketed and discussed as a tissue-repair "stack." It is not a single chemical entity. There is no combined molecular weight, no CAS number for the pair, and no standardized BPC-157:TB-500 ratio. The blend is two distinct synthetic peptides handled together, and the most useful way to read it is one constituent at a time.
BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV (~1419.5 Da), derived from a partial sequence of a protein found in human gastric juice [1]. In the blend it acts as the local cytoprotective and pro-angiogenic leg: it up-regulates VEGFR2, modulates the nitric-oxide system, and sensitizes tendon fibroblasts to growth-hormone-driven proliferation [2][5].
TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ (~889 Da), corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4 [8]. Its proposed role is cytoskeletal: the LKKTETQ helix binds monomeric G-actin one-to-one, regulating the actin dynamics that drive cell migration and re-epithelialization [3][4]. One caveat travels with TB-500 everywhere on this site: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer [4].
The two peptides are structurally unrelated, different in size, and act through largely non-overlapping pathways. That non-overlap is exactly the argument the blend rests on — and exactly why "synergy" remains a theoretical extrapolation rather than a measured result. This site reads each leg separately across the BPC-157 and TB-500 angiogenesis research, the dosing context, and the safety record, and indexes the common questions in one place.
Why the research community pairs BPC-157 with TB-500
The pairing rationale is complementary coverage. BPC-157's local angiogenic and cytoprotective signal is proposed to handle the perfusion-and-survival side of repair, while TB-500's cytoskeletal cell-migration signal is proposed to handle the cell-movement side — so the two are said to cover different stages of tissue repair from different directions [2][4].
That logic is clean on paper. The evidence underneath it is not a combination study. No peer-reviewed work has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies — 35 preclinical, only one human — found "no clinical safety data," and makes no mention of TB-500 or any blend at all [9]. The combination is an extrapolation from two separately characterized mechanisms, not a finding.
Why BPC-157 and TB-500 Are Combined
The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair [2][4]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together [9].
Why BPC-157 and TB-500 Are Combined (the Wolverine stack)
The stack pairs a perfusion-and-survival signal with a cell-migration signal. BPC-157 promotes VEGFR2-driven angiogenesis and fibroblast survival [2][7]; TB-500/Thymosin Beta-4 promotes the actin-regulated migration of endothelial, epithelial, and progenitor cells [3][4]. The pairing is mechanistically coherent and clinically unproven — there is no controlled combination trial.
The blend is also distributed through non-regulated channels, so product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated "Wolverine" material are not guaranteed [8]. For where regulated access actually stands, see Wolverine legal status and FDA 503A category.
What the blend is studied for
The research base for both constituents is overwhelmingly preclinical and overwhelmingly rodent. For BPC-157, the most-cited single result is tendon: 10 microg/kg accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and in vitro reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1]. For TB-500's parent protein, a consolidated review describes Thymosin Beta-4 binding actin, mobilizing cells, reducing myofibroblast number, limiting inflammation, and promoting angiogenesis [4].
These are single-compound, animal-model findings. The blend itself has no controlled efficacy study, and the human record for the individual constituents is thin: BPC-157 has three small pilot studies, and "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide [9]. The BPC-157 and TB-500 dosage in animal models is summarized in research terms, the side effects and safety signals are catalogued honestly, and the frequently asked questions collect the rest in one index.
What Is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 [8]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack; it is not a single chemical entity and is not an approved product anywhere.
What Is the Wolverine Peptide Blend?
The Wolverine peptide blend is a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It has no CAS number, no standardized ratio, and no approved indication [8]. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg BPC-157 + 10 mg TB-500), but no standardized composition is clinically validated.
What the Blend Is Studied For
Preclinical research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, and angiogenesis [1][4]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study, and the 2025 systematic review of BPC-157 graded the evidence at level IV-V, the lowest tiers [9].
Two compounds, told apart
Reading the blend well means keeping its two halves distinct. The site marks every finding with the constituent it belongs to — BPC-157 on one channel, TB-500 on the other — so a reader sees at a glance which leg of the blend an evidence point comes from.
How BPC-157 Works Compared to TB-500
BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, and growth-hormone-receptor sensitization of tendon fibroblasts [2][5][6]. TB-500 supplies an intracellular actin-sequestration signal: 1:1 G-actin binding via the LKKTETQ motif that regulates cell migration [3]. They act through complementary but largely non-overlapping pathways.
BPC-157 vs TB-500: Two Distinct Compounds
They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways [1][2][5]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin [3][8]. Different sequences, different sizes, different mechanisms.
What Is the Difference Between BPC-157 and TB-500?
They are structurally unrelated peptides. BPC-157 (GEPPPGKPADDAGLV, ~1419.5 Da) acts via VEGFR2-Akt-eNOS and growth-hormone-receptor signaling [1][2]; TB-500 (Ac-LKKTETQ, ~889 Da) acts by sequestering monomeric G-actin through its LKKTETQ motif [3][8]. Different sequence, different size, different mechanism — paired only by a shared tissue-repair rationale.